Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Down 57.0% in April

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a large drop in short interest in April. As of April 15th, there was short interest totalling 115,600 shares, a drop of 57.0% from the March 31st total of 268,900 shares. Approximately 2.6% of the company’s shares are sold short. Based on an average daily trading volume, of 111,900 shares, the days-to-cover ratio is currently 1.0 days.

Salarius Pharmaceuticals Price Performance

Salarius Pharmaceuticals stock remained flat at $0.50 during trading hours on Friday. 4,071 shares of the company’s stock traded hands, compared to its average volume of 39,317. The business’s 50-day simple moving average is $0.56 and its 200-day simple moving average is $0.62. Salarius Pharmaceuticals has a 12 month low of $0.43 and a 12 month high of $2.31.

Salarius Pharmaceuticals (NASDAQ:SLRX) last posted its quarterly earnings results on Friday, March 22nd. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($1.01) by $0.79. Research analysts expect that Salarius Pharmaceuticals will post -26.8 earnings per share for the current year.

Institutional Investors Weigh In On Salarius Pharmaceuticals

An institutional investor recently raised its position in Salarius Pharmaceuticals stock. Armistice Capital LLC lifted its holdings in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) by 105.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 225,000 shares of the company’s stock after purchasing an additional 115,364 shares during the period. Armistice Capital LLC owned about 5.71% of Salarius Pharmaceuticals worth $148,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.88% of the company’s stock.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.